<?xml version='1.0' encoding='utf-8'?>
<document id="28656193"><sentence text="A preliminary review of warfarin toxicity in a tertiary hospital in Cape Town, South Africa." /><sentence text="Warfarin is a widely used anticoagulant for the prevention and treatment of thromboembolism"><entity charOffset="0-8" id="DDI-PubMed.28656193.s2.e0" text="Warfarin" /></sentence><sentence text=" We conducted a retrospective review to determine the causes and management of warfarin toxicity of patients admitted to Tygerberg hospital between June 2014 and June 2015" /><sentence text="" /><sentence text="We identified and evaluated 126 patients who met the inclusion criteria" /><sentence text=" The cause of warfarin toxicity was identified and addressed in only 14" /><sentence text="3% (18/126) of patients" /><sentence text=" Where the cause was identified, 56% (10/18) was due to dosing errors and 17% (3/18) drug-drug interaction (DDI)" /><sentence text=" However, 77% (97/126) of patients were retrospectively identified as receiving concomitant medicines known to interact with warfarin at the time of admission" /><sentence text=" Twenty-eight percent (35/126) of patients presented with major bleeding, which included seven cases of intracranial haemorrhage" /><sentence text=" Patients were admitted for a median of eight days at an average treatment cost of R10 578" /><sentence text="" /><sentence text="We found that warfarin toxicity carries significant mortality and cost, but little attention is paid to the causes of toxicity" /><sentence text="" /></document>